Evidence map›Paper›PMID 34120397›Full record

ArticleInternational journal of clinical practice2021

Impact of sertraline daily treatment regimen on adherence, persistence and healthcare resource utilisation in patients with major depressive disorder or obsessive-compulsive disorder: A real-world evidence analysis from the United States.

Gang Wang, Tianmei Si, Joseph S Imperato, LiLi Yang, Kelly H Zou, Ying Olive Jin, Elizabeth A Pappadopulos, Lei Yan, Jim Z Li, Wei Yu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Gang WangThe National Clinical Research Center for Mental Disorders, Beijing Anding Hospital Affiliated to Capital Medical University, Beijing, China.
Tianmei SiNational Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), NHC Key Laboratory of Mental Health (Peking University), Peking University Sixth Hospital, Peking University Institute of Mental Health, Beijing, China.
Joseph S ImperatoGlobal Medical and Clinical, Viatris, Canonsburg, PA, USA.
LiLi YangMedical and Clinical Research Department, Greater China Region, Viatris, Beijing, China.
Kelly H ZouGlobal Medical and Clinical, Viatris, Canonsburg, PA, USA.
Ying Olive JinMedical and Clinical Research Department, Greater China Region, Viatris, Beijing, China.
Elizabeth A PappadopulosGlobal Medical and Clinical, Viatris, Canonsburg, PA, USA.
Lei YanMedical and Clinical Research Department, Greater China Region, Viatris, Beijing, China.
Jim Z LiGlobal Medical and Clinical, Viatris, Canonsburg, PA, USA.
Wei YuMedical and Clinical Research Department, Greater China Region, Viatris, Beijing, China.
Tris Pharma (United States) · USBeijing Anding Hospital · CNPeking University · CN

Funding

Upjohn
6 · The paper itself

Abstract

objectiveTo generate real-world evidence (RWE) from the United States to assess the impact of pill burden and the importance of achieving a stable daily dose of sertraline (time taken, number of dose adjustments needed) on adherence/persistence and healthcare resource utilisation (HCRU).

methodsRetrospective analysis of the PharMetrics

resultsOf 224 412 eligible patients, 108 729 stabilised on sertraline (50, 100 or 150 mg/d) and formed Cohorts 1-5. Stabilised patients on lower pill burden had statistically higher adherence and were more likely to remain persistent throughout 1-year post-index period vs patients on higher pill burden but same overall dose (100 mg/d [Cohort 2 vs 3] and 150 mg/d [Cohort 4 vs 5], respectively). Patients who did not stabilise had significantly lower adherence/persistence vs patients who achieved stable daily dose (Cohorts 1-5 combined). Persistence improved when stable daily dose was achieved quickly (within 1-4 months) and efficiently (within 1-3 dose adjustments). Probability of HCRU increased for patients who did not stabilise on their initial prescription.

conclusionSimplifying treatment regimen and decreasing pill burden improved adherence and/or persistence with sertraline therapy (100 or 150 mg/d). Patients achieving stable daily dose of sertraline in an efficient and timely manner were more likely to remain persistent throughout 1-year follow-up.

Indexed as

Major Depressive DisorderObsessive-Compulsive DisorderHumansMedication AdherencePatient Acceptance of Health CareRetrospective StudiesSertralineUnited StatesSertraline

Identifiers

PMID34120397
PMCPMC8518919
OpenAlexW3172917326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.